CAR-Tregs for the treatment of systemic lupus erythematosus

admin_vjr_user — Fri, 31 Dec 2021 10:38:51 +0000

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes the rationale behind the delivery of regulatory T cells (Tregs) for the treatment of autoimmune diseases, given their ability to maintain self-tolerance and suppress the immune response. Dr Bonini also introduces ongoing research employing chimeric antigen receptor (CAR) technology to redirect Treg activity, with the aim of restoring immune tolerance in systemic lupus erythematosus (SLE). This interview took place at the European Society of Gene & Cell Therapy (ESGCT) Virtual Congress 2021.

CAR-Treg therapy for systemic lupus erythematosus

Marta Palhas — Fri, 26 Feb 2021 14:08:22 +0000

Regulatory T-cells (Tregs) are a subgroup of T-cells that function to maintain homeostasis and prevent autoimmunity. Matteo Doglio, MD, IRCCS Ospedale San Raffaele, Milan, Italy, discusses CAR-Treg therapy for systemic lupus erythematosus (SLE). SLE is a chronic inflammatory autoimmune disorder characterized by the production of autoantibodies B-cell derived plasma cells. The use of CARs combined with regulatory T-cells allows to boost the normal suppressive activities of lymphocytes and block the inflammatory response in autoimmune diseases. Results show that the CAR-Treg product was able to suppress the activity of normal lymphocytes in vitro. More importantly, in an in vivo model, the cells were able to slow down the disease’s progression. Dr Doglio highlights that the product needs to be improved, but the preliminary results are very encouraging. This interview took place during the 3rd European CAR T-cell Meeting.

Systemic Lupus Erythematosus – VJRegenMed

CAR-Tregs for the treatment of systemic lupus erythematosus

CAR-Treg therapy for systemic lupus erythematosus